October 2018- Volume 14, Issue 10

In this Issue

Preclinical

Peering into the preclinical realm

Peering into the preclinical realm

A roundup of recent preclinical data presentations and journal publications

Possibility grows for pan-Ebola vaccine

Possibility grows for pan-Ebola vaccine

Scripps team discovers potential target mechanisms that could enable the treatment of multiple strains of Ebolavirus

More coverage on Coversin

More coverage on Coversin

Akari reports on the effects of its bimodal Coversin in inflammatory indications

FR104 offers control of graft-versus-host disease

FR104 offers control of graft-versus-host disease

OSE Immunotherapeutics’ study of the CD28 antagonist was published in Journal of Clinical Investigation

Clinical Trials

Effective option for the skin

Effective option for the skin

Clinical trial shows monoclonal antibody drug effective against pruritus

Dupixent delivers strong Phase 3 results

Dupixent delivers strong Phase 3 results

Patients saw improvements in skin clearing and quality of life

Out of the starting gate

Out of the starting gate

A roundup of clinical trial startups and initial breakthroughs

Diagnostics

Diagenode snaps up NXT-Dx

Diagenode snaps up NXT-Dx

The transaction expands Diagenode’s epigenetics and epigenomics offerings

‘A clear benefit’

‘A clear benefit’

Agena, PerkinElmer partnership emphasizes quality, speed and sensitivity in liquid biopsy

It’s all in the volume measurement

It’s all in the volume measurement

Data show Daxor’s BVA-100 is superior to formula-based estimates of blood volume in assessing heart failure patients

A ‘breakthrough biomarker’ for rheumatoid arthritis

A ‘breakthrough biomarker’ for rheumatoid arthritis

Novel test now available to aid in detection and management of debilitating condition

Discovery

Say yes to YRSACT

Say yes to YRSACT

Scripps scientists find new lead to combat low platelet counts

Infectious disease research reaches across borders

Infectious disease research reaches across borders

New collaboration announced between Boehringer Ingelheim and Tsinghua University

Getting together

Getting together

A roundup of recent discovery-related deals and agreements

AI, drug discovery and rare disease

AI, drug discovery and rare disease

Pharma executive Kate Hilyard joins Healx to drive integration effort forward

A new answer for amoeba treatment

A new answer for amoeba treatment

Skaggs researchers from UCSD repurpose approved drugs to treat fatal brain infection

Contract Services

Partnering for efficiency

Partnering for efficiency

Companies collaborate on cloud-based IT validation software for life sciences

Building better models

Building better models

CrownBio licenses translational breast cancer models of resistance and metastasis

Extending the value

Extending the value

CRO announces $7.8M extension agreement for OmniComm’s TrialOne

Research & Development

Bispecific boon

Bispecific boon

Aptevo will use Genedata platform to streamline cancer immunotherapy R&D

More than just skin

More than just skin

Otezla post-hoc sub-analyses showed meaningful improvements in metrics beyond skin clearance

Welcome to the real world

Welcome to the real world

PAREXEL and Datavant partner to enhance drug development and commercialization

Transcription factors and TransSyn

Transcription factors and TransSyn

Multicenter European team reveals computational method for predicting how to convert subpopulations of cells

All in the epigenetics

All in the epigenetics

Team finds epigenetic reason for drug resistance in deadly melanoma and identifies potential ways to counteract it

Business & Government Policy

Boehringer Ingelheim acquires all ViraTherapeutics shares

Boehringer Ingelheim acquires all ViraTherapeutics shares

The German company seeks to develop next-generation viral-based immuno-oncology therapies

BIA Separations expands

BIA Separations expands

New lab processing facility will support integrated optimization of upstream and downstream process development

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

VistaGen acquires worldwide license of phase 3-ready CNS drug

VistaGen acquires worldwide license of phase 3-ready CNS drug

Candidate from Pherin Pharmaceuticals is meant for as-needed treatment of social anxiety disorder

Special Reports

Editor's Focus

Editor’s focus: The struggle against schizophrenia

Editor’s focus: The struggle against schizophrenia

Therapeutics for mental illness have always been tricky, but schizophrenia seems a bit more intractable than most

Commentary

New recruits for 2019

New recruits for 2019

Opportunities for Ph.D. students entering the workforce go beyond just academia

Guest Commentary: Bringing precision medicine to the evaluation and treatment of mental illness

Guest Commentary: Bringing precision medicine to the evaluation and treatment of mental illness

What we do know about the genetics, neurobiology and behavioral science of mental illness can be used to improve diagnosis and treatment

Feature

Focus Feature on Breast Cancer

Focus Feature on Breast Cancer

Beginning with a story about Salk researchers finding a ‘master control switch' for aggressive breast cancer, we give you a quick roundup of recent breast cancer news in honor of Breast Cancer Awareness Month
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue